Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el miércoles 18/06/2025 al final de la jornada laboral. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
184
resultados
Última actualización
21/06/2025 [08:13:00]
Resultados 25 a 50 de 184
Resumen de: WO2025121804A1
Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting porcine epidemic diarrhea virus, a one-step diagnostic kit for porcine epidemic diarrhea, and a one-step diagnostic method for porcine epidemic diarrhea. Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting SARS-CoV-2 nucleoprotein, a one-step SARS-CoV-2 diagnostic kit, and a one-step SARS-CoV-2 diagnostic method.
Resumen de: WO2025122814A1
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
Resumen de: KR20250085005A
펩타이드, 항체 또는 이의 항원 결합 단편, 핵산, 재조합 발현 벡터, 세포, SARS-CoV-2 핵단백질 검출용 물질, 원스텝 SARS-CoV-2 진단 키트 및 원스텝 SARS-CoV-2 진단 방법이 개시된다.
Resumen de: EP4566625A1
The present invention relates to a production method of an inactivated SARS-CoV-2 vaccine, the method including: a step of bringing a SARS-CoV-2 containing solution or an inactivated SARS-CoV-2 containing solution into contact with a cellulose sulfate ester gel at a pH of 8 or more and 10 or less to adsorb the SARS-CoV-2 or the inactivated SARS-CoV-2 to the gel; then removing impurities; and then eluting and recovering the SARS-CoV-2 or the inactivated SARS-CoV-2.
Resumen de: US2024166587A1
The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH—, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.
Resumen de: CN119731159A
The present disclosure relates to compounds of formula (I): # imgabs0 # and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of viral infections, such as coronavirus infections.
Resumen de: US12324835B1
An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. An application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2 is further disclosed. Compared to an mRNA vaccine encoding separately corresponding antigens, the provided mRNA vaccine encoding a fusion antigen can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine is obtained by synthesizing a single mRNA molecule and encapsulating the single mRNA within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.
Resumen de: KR20250083067A
본 발명은 계통수 분석 기반 교차 면역원성을 갖는 SARS-CoV-2 스파이크 모자이크 항원 및 이를 포함하는 백신에 관한 것으로서, 본 발명의 SARS-CoV-2 바이러스 모자이크 항원은 SARS-CoV-2 바이러스 변이주의 스파이크 단백질 서열을 모자이크 기법을 통해 조합하고 추가적인 아미노산 잔기를 치환하여, 초기 prototype, 알파 변이주, 베타 변이주, 감마 변이주, 델타 변이주 및 오미크론 변이주 등과 같은 다양한 SARS-CoV-2 변이주에 대한 범용성을 가지는 백신의 용도로서 유용하게 사용될 수 있다.
Resumen de: AU2025203389A1
Abstract A vaccine composition comprising a lyophilized, adenovirus-based expression vector encoding a disease antigen, and a stabilizing compound, such as aragonite. The disease antigen may comprise a viral protein or fragment thereof, such as a SARS-CoV2 virus protein. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.
Resumen de: US2025177469A1
The present invention relates to a use of a novel Sanguisorba officinalis Linne extract to inhibit SARS-CoV-2 virus 3CL protease and RdRp activity. The composition including the Sanguisorba officinalis Linne extract of the present invention as an active ingredient inhibits 3CL protease and RdRp activity and thus is effective in preventing or treating infection by SARS-CoV-2 and a variant virus thereof.
Resumen de: US2025179581A1
Methods and devices for utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP) to detect target DNA and RNA sequences for diagnostic and experimental assays, such as those for diagnosing and quantifying diseases, such as colorectal cancer and gastrointestinal disease, or pathogens, such as SARS-COV-2.
Resumen de: US2025177541A1
Disclosed herein are methods of treating a lung disorder. In some embodiments, the lung disorder includes an acute respiratory syndrome. In some embodiments, the treatment includes administering to a subject in need thereof, a modified Serp-1 protein. The modified Serp-1 protein may include a therapeutic enhancing moiety. In some embodiments, the therapeutic enhancing moiety is a water soluble polymer such as polyethylene glycol.
Resumen de: US2025180506A1
This present invention provides a system, method, and device for rapidly screening individuals at a high rate of speed. The invention features a method, system and device that analyzes an individual's body odors to determine the presence or absence of a disease such as COVID-19 and/or its variants. The invention allows for real-time testing for a pathogen, a disease, or other condition of interest that is especially useful when testing every individual entering or exiting a venue or transitioning through any controlled entry or exit zone demarcated by a portal, passage, security zone, or gate, etc. This testing requires no invasive sampling—or even touch contact—between the device or device operator and the person being tested. The device features a sensing surface whose electronic activity is a function volatile organic compounds (body odor) in the immediate vicinity of its surface.
Resumen de: US2025180560A1
Provided herein are, in various embodiments, methods and kits for assaying one or more virions. In certain embodiments, the methods and kits of the disclosure provide for the calculation of virion titer and/or virion infectivity. In still further embodiments, the disclosure provides for methods and kits for enhancing assaying of viruses such as SARS-CoV-2.
Resumen de: US2025177428A1
Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.
Resumen de: US2025179152A1
The present disclosure relates to compositions and methods for the treatment and/or prevention of SARS-COV-2 infections. In one embodiment the method comprises the delivery of a pharmaceutical composition comprising a SARS-COV-2 neutralizing synthetic protein, optionally wherein the protein is a trimeric protein composed of designed ankyrin repeat protein (DARPin) fused with a T4 foldon peptide that is administered non-invasively such as by nasal inhalation.
Resumen de: US2025177481A1
The invention relates to polypeptides derived from SCO-spondin for increasing or enhancing the basal excitatory synaptic transmission, notably glutamatergic neurotransmission. More particularly the invention relates to said polypeptides for increasing or enhancing glutamatergic neurotransmission in diseases or conditions comprising psychiatric disorders; drug addiction; viral infection (such as coronaviruses, e.g. SARS CoV2) related neurological symptoms; NMDA receptor (NMDAr) and/or AMPA receptor (AMPAr) deficiency related disease, notably anti-NMDAr encephalitis; vegetative state, and hypoxic brain injury. The present invention also relates to methods of treatment.
Resumen de: US2025177434A1
An antiviral agent is provided, having a phosphorodiamidate morpholino oligomer with an antisense sequence to a portion of a genome of a strain of a coronavirus. The coronavirus may be SARS-CoV-2 or another βCoV. The antiviral agent finds many uses, such as in a pharmaceutical composition, a method of treating coronavirus-mediated disease, a method of preventing coronavirus-mediated disease, a method of reducing or preventing the replication of coronavirus in a host cell, a method of controlling the spread of coronavirus in donated tissue, a treated tissue sample, and in the manufacture of a medicament for the treatment or prevention or coronavirus-mediated disease.
Resumen de: US2025179151A1
Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.
Resumen de: US2024166587A1
The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH—, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.
Resumen de: KR20250077973A
본 발명은 개체의 아르기닌(Arginine) 대사경로 활성화를 확인하는 단계;를 포함하는, COVID-19 코로나바이러스 변이주 감염의 모니터링 방법에 관한 것으로, 본 발명의 모니터링 방법은 COVID-19 코로나바이러스 변이주 감염 개체에서 아르기닌 대사에 관여하는 전사체 및 대사체의 변화를 확인함으로써, 효과적으로 COVID-19 코로나바이러스 변이주 감염을 진단할 수 있다.
Resumen de: AU2023356620A1
The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Resumen de: AU2023361023A1
The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.
Resumen de: WO2025111412A1
Small anti-inflammatory peptide for blocking NF-κB are disclosed herein. The peptides as well as compositions including the peptides can be administered to inhibit cytokine production and/or inhibit pulmonary inflammation in a subject in need. Particularly embodiments include administration to a subject suffering from coronavirus disease 2019 (COVID-19).
Nº publicación: WO2025108306A1 30/05/2025
Solicitante:
SHANGHAI RNACURE BIOPHARMA CO LTD [CN]
\u4E0A\u6D77\u84DD\u9E4A\u751F\u7269\u533B\u836F\u6709\u9650\u516C\u53F8
Resumen de: WO2025108306A1
Disclosed are a VZV antigen variant, a nucleic acid, a pharmaceutical composition and the use thereof. The VZV antigen variant has a difference of Y582G compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has deletions at positions 561-623, 569-623 or 574-623 compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has a modification of a transmembrane region and intracellular region of a protein compared to an amino acid sequence as set forth in SEQ ID NO: 1, wherein the modification of the transmembrane region and intracellular region of the protein involves the replacement of a transmembrane region and intracellular region of an original VZV antigen with a transmembrane region of a SARS-CoV-2Spike protein or a transmembrane region of an influenza H protein. The VZV antigen variant has a stronger immunogenicity than the VZV antigen in the prior art, can achieve a higher titer of binding antibodies, and has a higher protection efficacy.
BOPI
Sede Electrónica
